Hot Investor Mandate: Corporate VC Firm Invests Up to $10M in Therapeutics and Digital Health in Areas that Strategically Align with Parent Company’s Interest Areas

23 Jun

A corporate venture capital firm with offices in USA and Western Europe invests from an evergreen fund. The firm interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $10 million over the life of an investment.  The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments; the fund’s allocations are ‘no strings attached’. The firm considers opportunities globally but focuses on Europe, Middle East and North America.

The firm is strategically mandated to invest in opportunities beyond the corporate’s core areas of business.  The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology, regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology), but will also consider opportunities in other indication areas that lie outside of the corporate’s present core therapeutic fields. Areas in which the parent company has strength, such as respiratory disorders and diabetes, will generally not receive investment from the firm. The firm generally invests in preclinical assets.

The firm invests in technologies of strategic importance to the parent company. The firm only invests in privately held companies. The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: